Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P16671
UPID:
CD36_HUMAN
Alternative names:
Fatty acid translocase; Glycoprotein IIIb; Leukocyte differentiation antigen CD36; PAS IV; PAS-4; Platelet collagen receptor; Platelet glycoprotein IV; Thrombospondin receptor
Alternative UPACC:
P16671; D9IX66; D9IX67; D9IX68; D9IX69; Q13966; Q16093; Q8TCV7; Q9BPZ8; Q9BQC2; Q9BZM8; Q9BZN3; Q9BZN4; Q9BZN5
Background:
Platelet glycoprotein 4, also known as CD36, is a multifunctional glycoprotein acting as a receptor for various ligands, including thrombospondin, fibronectin, collagen, and oxidized low-density lipoprotein. It plays a crucial role in angiogenesis, inflammation, fatty acid metabolism, and the immune response. CD36's involvement in fatty acid transport into cells supports muscle lipid utilization, adipose energy storage, and gut fat absorption.
Therapeutic significance:
CD36 deficiency leads to disorders like Platelet glycoprotein IV deficiency, characterized by macrothrombocytopenia, and is implicated in coronary heart disease due to its role in atherosclerosis. Understanding CD36's functions and interactions offers a pathway to novel treatments for these conditions, highlighting its potential as a target for therapeutic intervention.